ImmunoQure Overview

  • Founded
  • 2011
  • Status
  • Private
  • Employees
  • 11
  • Latest Deal Type
  • Series A
  • Investors
  • 1

ImmunoQure General Information


Developer of patient-selected antibodies intended to offer treatment of inflammatory and autoimmune diseases. The company's autoantibodies help in retrieving meaningful, natural human autoantibodies against relevant human drug targets that are the root cause of common diseases, enabling healthcare professionals to identify and develop the most relevant autoantibodies from highly selected patient populations based on defined aspects of their clinical history.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • Königsallee 90
  • 40212 Düsseldorf
  • Germany
+49 0211 00000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

ImmunoQure Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC (Series A) 13-Dec-2011 Completed Startup
To view ImmunoQure’s complete valuation and funding history, request access »

ImmunoQure Executive Team (8)

Name Title Board Seat Contact Info
Edward Stuart Ph.D Co-Founder & Chief Executive Officer
Adrian Hayday Ph.D Scientific Co-Founder & Board Member
Kai Kisand Ph.D Scientific Co-Founder & Board Member
Pärt Peterson Ph.D Scientific Co-Founder & Board Member
Annamari Ranki Ph.D Scientific Co-Founder
You’re viewing 5 of 8 executive team members. Get the full list »

ImmunoQure Board Members (4)

Name Representing Role Since
Adrian Hayday Ph.D ImmunoQure Scientific Co-Founder & Board Member 000 0000
Kai Kisand Ph.D ImmunoQure Scientific Co-Founder & Board Member 000 0000
Karsten Henco Ph.D Self Chairman of the Board 000 0000
Pärt Peterson Ph.D ImmunoQure Scientific Co-Founder & Board Member 000 0000
To view ImmunoQure’s complete board members history, request access »

ImmunoQure Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ImmunoQure Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
HS LifeSciences Venture Capital Minority 000 0000 000000 0
To view ImmunoQure’s complete investors history, request access »